Page last updated: 2024-10-24

IMP metabolic process

Definition

Target type: biologicalprocess

The chemical reactions and pathways involving IMP, inosine monophosphate. [GOC:go_curators]

The IMP metabolic process encompasses the biosynthesis and degradation of inosine monophosphate (IMP), a crucial purine nucleotide involved in various cellular functions. IMP serves as a precursor for both adenosine monophosphate (AMP) and guanosine monophosphate (GMP), the building blocks of RNA and DNA.

The biosynthesis of IMP commences with the initial commitment step catalyzed by the enzyme glutamine-PRPP amidotransferase, which converts phosphoribosyl pyrophosphate (PRPP) to phosphoribosylamine. Subsequent steps involve the incorporation of glycine, formate, and aspartate, leading to the formation of IMP.

The degradation of IMP can occur through two pathways: the purine nucleoside phosphorylase pathway and the xanthine oxidase pathway. The purine nucleoside phosphorylase pathway converts IMP to inosine, which is then further degraded to hypoxanthine. The xanthine oxidase pathway involves the oxidation of hypoxanthine to xanthine and ultimately to uric acid.

IMP metabolism is tightly regulated to ensure proper purine nucleotide homeostasis. Feedback inhibition by AMP and GMP regulates the activity of key enzymes involved in IMP biosynthesis. Moreover, the intracellular concentration of IMP influences the synthesis of AMP and GMP, thus impacting the overall purine nucleotide pool.

IMP metabolic process plays a critical role in cell growth, proliferation, and differentiation. Disruptions in IMP metabolism have been linked to various diseases, including gout, Lesch-Nyhan syndrome, and certain cancers. Therefore, understanding the intricacies of IMP metabolism holds significant implications for therapeutic strategies targeting these disorders.'
"

Proteins (2)

ProteinDefinitionTaxonomy
Adenylosuccinate synthetase isozyme 2An adenylosuccinate synthetase isozyme 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P30520]Homo sapiens (human)
Hypoxanthine-guanine phosphoribosyltransferaseA hypoxanthine-guanine phosphoribosyltransferase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P00492]Homo sapiens (human)

Compounds (12)

CompoundDefinitionClassesRoles
chrysenechrysene : An ortho-fused polycyclic arene found commonly in the coal tar.

chrysene: structure in Merck Index, 9th ed, #2252
ortho-fused polycyclic areneplant metabolite
hadacidinhadacidin : A monocarboxylic acid that is N-hydroxyglycine in which the hydrogen attached to the nitrogen is replaced by a formyl group. It was originally isolated from cultures of Penicillium frequentans.

hadacidin: inhibitor of AMP synthesis; RN given refers to parent cpd; structure
aldehyde;
monocarboxylic acid;
N-hydroxy-alpha-amino-acid
antimicrobial agent;
antineoplastic agent;
Penicillium metabolite;
teratogenic agent
6-chrysenamine6-chrysenamine: may cause splenic atrophy and leukopenia; minor descriptor (76-84); on-line & Index Medicus search PHENANTHRENES (76-84)carbopolycyclic compound
6-nitrochrysene6-nitrochrysene: RN given refers to cpd with locant for nitro group in position 6carbopolycyclic compound
mercaptopurinemercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.

Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.

purine-6-thiol : A thiol that is the tautomer of mercaptopurine.
aryl thiol;
purines;
thiocarbonyl compound
anticoronaviral agent;
antimetabolite;
antineoplastic agent
thioguanine anhydrousThioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.

tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.
2-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
guanosine monophosphateguanosine 5'-monophosphate : A purine ribonucleoside 5'-monophosphate having guanine as the nucleobase.

Guanosine Monophosphate: A guanine nucleotide containing one phosphate group esterified to the sugar moiety and found widely in nature.
guanosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate
biomarker;
Escherichia coli metabolite;
metabolite;
mouse metabolite
guanine2-aminopurines;
oxopurine;
purine nucleobase
algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
hypoxanthinenucleobase analogue;
oxopurine;
purine nucleobase
fundamental metabolite
inosinic acidInosine Monophosphate: Inosine 5'-Monophosphate. A purine nucleotide which has hypoxanthine as the base and one phosphate group esterified to the sugar moiety.inosine phosphate;
purine ribonucleoside 5'-monophosphate
Escherichia coli metabolite;
human metabolite;
mouse metabolite
allopurinolallopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.

Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.
nucleobase analogue;
organic heterobicyclic compound
antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
azaguanine8-azaguanine : A triazolopyrimidine that consists of 3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidine bearing amino and oxo substituents at positions 5 and 7 respectively.

Azaguanine: One of the early purine analogs showing antineoplastic activity. It functions as an antimetabolite and is easily incorporated into ribonucleic acids.
nucleobase analogue;
triazolopyrimidines
antimetabolite;
antineoplastic agent;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor